Dramatic improvement of myotonia permanens with flecainide: a two-case report of a possible bench-to-bedside pharmacogenetics strategy.
Jean-François
JF
Desaphy
Anna
A
Modoni
Mauro
M
Lomonaco
Diana Conte
DC
Camerino
D005260:Female; D005424:Flecainide / Q000008:administration & dosage / Q000627:therapeutic use*; D006801:Humans; D008297:Male; D009154:Mutation; D009224:Myotonia Congenita / Q000188:drug therapy* / Q000235:genetics; D062553:NAV1.4 Voltage-Gated Sodium Channel / Q000235:genetics*; D009679:Nuclear Family; D010597:Pharmacogenetics; D016896:Treatment Outcome; D061567:Voltage-Gated Sodium Channel Blockers / Q000008:administration & dosage / Q000627:therapeutic use*
D062553:NAV1.4 Voltage-Gated Sodium Channel; D061567:Voltage-Gated Sodium Channel Blockers; D005424:Flecainide